Alkermes
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
ALKS Key Statistics
Stock Snapshot
With a market cap of 4.8B, Alkermes(ALKS) trades at $29.04. The stock has a price-to-earnings ratio of 14.37.
On 2025-11-16, Alkermes(ALKS) stock moved within a range of $28.67 to $31.26. With shares now at $29.04, the stock is trading +1.3% above its intraday low and -7.1% below the session's peak.
Trading volume for Alkermes(ALKS) stock has reached 5.69M, versus its average volume of 3.72M.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
ALKS News
After Avadel (AVDL) announced an unsolicited proposal from Lundbeck (HLBBF) to be acquired for up to $23 per share, Truist argues that the proposal “would only...
Danish drugmaker H. Lundbeck has made an unsolicited bid worth up to $2.25 billion for Avadel Pharmaceuticals. Carsten Snejbjerg/Bloomberg News Danish drugmake...
Alkermes (ALKS) notes the announcement made by Avadel Pharmaceuticals (AVDL) regarding a possible offer by H. Lundbeck A/S to acquire all the issued and to be i...
Analyst ratings
81%
of 16 ratingsMore ALKS News
Alkermes (ALKS) shared positive topline data from its Vibrance-2 phase 2 study evaluating alixorexton in narcolepsy type 2. The study showed clinically meaningf...
Bank of America Securities analyst Jason Gerberry maintained a Hold rating on Alkermes yesterday and set a price target of $34.00. Meet Your ETF AI Analyst Disc...
Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in n...
Evercore ISI said the firm disagrees with the Street reaction on Alkermes (ALKS), adding that the “Street has had a confused reaction to all the new data out of...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
In a report released today, Ami Fadia from Needham maintained a Buy rating on Alkermes, with a price target of $44.00. Meet Your ETF AI Analyst Discover how Tip...